Company news

Shenzhen Chipscreen Biosciences Co. Ltd. Class A (SSE:688321) news

Shenzhen Chipscreen Biosciences Co. Ltd. Class A news releases on 6ix. Latest, Aug 26, 2026: "Shenzhen Chipscreen Biosciences Co., Ltd."Announcement…

Shenzhen Chipscreen Biosciences Co. Ltd. Class A (SSE:688321) news

Press releases & updates

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Listing and Trading of Restricted Shares from 2024 Private Placement of Shares

"Shenzhen Chipscreen Biosciences Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure Regarding Acceptance of Clinical Trial Application for NW001

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Adjustment of Related Matters for the 2026 Restricted Share Incentive Plan

"Shenzhen Chipscreen Biosciences Co., Ltd."Self-inspection Report on Trading in the Company's Shares by Insiders with Access to Inside Information in Relation to the 2026 Restricted Share Incentive Plan

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS43158 Tablets

"Shenzhen Chipscreen Biosciences Co., Ltd."Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Implementation Result of Shares Repurchase and Share Changes

"Shenzhen Chipscreen Biosciences Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026

"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Conversion Result of Convertible Bonds and Share Changes

Announcement on Follow-up Credit Rating Results of "Chipscreen Convertible Bonds"

Announcement on Progress in Repurchasing Shares

Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple

Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer

Shareholders' Inquiry Transfer Plan

Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SAR

Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property Administration

Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion Suspension

Announcement on Convening the Q1 2026 Performance Briefing

Report for Q1 2026

Indicative Announcement on the Adjustment of Convertible Bond Conversion Prices and Continuous Suspension for Convertible Shares during the Implementation of 2025 Annual Dividend Distribution

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Conversion Result of Convertible Bonds and Share Changes

Announcement on Resolutions of the 25th Meeting of the 3rd Board of Directors

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of CS08399 Tablets

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution

Announcement on Adjustment of the Conversion Price and Trading Suspension/Resumption of "Chipscreen Convertible Bonds" Due to Private Placement of Shares

Announcement on the Chairman's Proposal to Repurchase Shares

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Signing Tripartite Supervision Agreement for Deposit of Raised Fund in Special Account

Announcement on Execution of a License and Distribution Agreement with Nizhpharm

Announcement on the Thawing of Partially Frozen Shares Held by a Shareholder Owning 5% or More of the Company’s Equity

Announcement on Proposed Participation of Connected Persons in the Subscription of Shares Issued to Specific Objects and Related Party Transaction

Announcement on Earnings Preannouncement for 2025

Indicative Announcement on "Chipscreen Convertible Bonds" Expected to Meet Conditions for Redemption

Announcement on Estimated Amount of Daily Related Party Transactions in 2026

Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Chiauranib Capsules

Announcement on Voluntary Disclosure of Approval of Chidamide for Market Release by the Pharmaceutical Administration Bureau, Macao SAR

Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets

Announcement on Voluntary Disclosure on the Acceptance of the Clinical Trial Application for CS08399 Tablets

Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

Announcement on Implementation Result of Shares Repurchase and Share Changes

Announcement on Voluntary Disclosure of the Inclusion of the Company’s Product in the National Medical Insurance Catalog

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Obtaining Reply of Registration Approval of Application for Issuance of Shares to Specific Objects from China Securities Regulatory Commission

Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale and Result of Shareholding Reduction